שווי כולל של החברה: aptevotherapeutics.com (APVO)

Aptevo Therapeutics (APVO) is moving toward active expansion within the oncology sphere, focusing on the efficacy of its primary developments. The company's success is based on the unique ADAPTIR system, which enables the creation of advanced antibodies. This chart reflects an Enterprise Value of -3.24. The current business valuation relies on the creation of precision immunotherapy that leverages T-cells to combat tumors with a low level of side effects.

For Aptevo Therapeutics (APVO), the high profit margins of its hemophilia drug make the business valuation highly sensitive to the scaling of its commercial base. By analyzing the enterprise value trends on GURU.Markets, an investor can determine the actual acquisition price of the asset, calculated as the sum of market capitalization and net debt, which allows for an objective assessment of the company's business model net of available cash.